Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Climb Bio (CLYM) and Boston Scientific (BSX)

Tipranks - Tipranks - Wed Mar 25, 7:36AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tarsus Pharmaceuticals (TARS), Climb Bio (CLYM) and Boston Scientific (BSX) with bullish sentiments.

Claim 30% Off TipRanks Premium

Tarsus Pharmaceuticals (TARS)

LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on Tarsus Pharmaceuticals today and set a price target of $95.00. The company’s shares closed last Monday at $64.13.

According to TipRanks.com, Brisebois is a 2-star analyst with an average return of 0.1% and a 38.3% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Centessa Pharmaceuticals, and Aquestive Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tarsus Pharmaceuticals with a $88.95 average price target, which is a 34.6% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock with a $64.51 price target.

See the top stocks recommended by analysts >>

Climb Bio (CLYM)

In a report released today, Matt Phipps from William Blair maintained a Buy rating on Climb Bio. The company’s shares closed last Monday at $6.54.

According to TipRanks.com, Phipps is a 4-star analyst with an average return of 4.9% and a 43.8% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Janux Therapeutics Inc, and Ionis Pharmaceuticals. ;'>

Climb Bio has an analyst consensus of Strong Buy, with a price target consensus of $16.67, representing a 172.4% upside. In a report issued on March 10, Raymond James also initiated coverage with a Buy rating on the stock with a $25.00 price target.

Boston Scientific (BSX)

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Boston Scientific, with a price target of $90.00. The company’s shares closed last Monday at $69.54, close to its 52-week low of $66.80.

According to TipRanks.com, Wise is a 1-star analyst with an average return of -2.0% and a 45.0% success rate. Wise covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., GE Healthcare Technologies Inc, and Treace Medical Concepts. ;'>

Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $106.30, a 51.8% upside from current levels. In a report issued on March 9, TD Cowen also maintained a Buy rating on the stock with a $100.00 price target.

Read More on TARS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).